Shenzhen Kangtai Biological Products Co Ltd - Asset Resilience Ratio
Shenzhen Kangtai Biological Products Co Ltd (300601) has an Asset Resilience Ratio of 12.24% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Shenzhen Kangtai Biological Products Co (300601) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Shenzhen Kangtai Biological Products Co Ltd's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Shenzhen Kangtai Biological Products Co to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Shenzhen Kangtai Biological Products Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300601 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.71 Billion | 12.24% |
| Total Liquid Assets | CN¥1.71 Billion | 12.24% |
Asset Resilience Insights
- Moderate Liquidity: Shenzhen Kangtai Biological Products Co Ltd has 12.24% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Shenzhen Kangtai Biological Products Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shenzhen Kangtai Biological Products Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Shenzhen Kangtai Biological Products Co Ltd (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Shenzhen Kangtai Biological Products Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.98% | CN¥1.69 Billion ≈ $247.13 Million |
CN¥14.10 Billion ≈ $2.06 Billion |
-2.95pp |
| 2024-12-31 | 14.93% | CN¥2.17 Billion ≈ $318.13 Million |
CN¥14.56 Billion ≈ $2.13 Billion |
+14.26pp |
| 2023-12-31 | 0.66% | CN¥100.02 Million ≈ $14.64 Million |
CN¥15.09 Billion ≈ $2.21 Billion |
-2.53pp |
| 2022-12-31 | 3.20% | CN¥440.83 Million ≈ $64.51 Million |
CN¥13.79 Billion ≈ $2.02 Billion |
-1.93pp |
| 2021-12-31 | 5.13% | CN¥725.57 Million ≈ $106.17 Million |
CN¥14.15 Billion ≈ $2.07 Billion |
-17.36pp |
| 2020-12-31 | 22.49% | CN¥2.16 Billion ≈ $315.37 Million |
CN¥9.58 Billion ≈ $1.40 Billion |
+17.96pp |
| 2017-12-31 | 4.52% | CN¥100.00 Million ≈ $14.63 Million |
CN¥2.21 Billion ≈ $323.50 Million |
+2.85pp |
| 2016-12-31 | 1.67% | CN¥26.80 Million ≈ $3.92 Million |
CN¥1.60 Billion ≈ $234.26 Million |
+0.17pp |
| 2015-12-31 | 1.50% | CN¥20.00 Million ≈ $2.93 Million |
CN¥1.33 Billion ≈ $195.18 Million |
+0.68pp |
| 2014-12-31 | 0.82% | CN¥11.00 Million ≈ $1.61 Million |
CN¥1.34 Billion ≈ $196.39 Million |
-0.49pp |
| 2013-12-31 | 1.31% | CN¥14.50 Million ≈ $2.12 Million |
CN¥1.11 Billion ≈ $161.97 Million |
-- |
About Shenzhen Kangtai Biological Products Co Ltd
Shenzhen Kangtai Biological Products Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of human vaccines in China and internationally. The company offers 13-valent pneumococcal polysaccharide conjugate vaccines (TT/DT); varicella vaccines (freeze-dried); hepatitis B vaccines; 23-valent pneumococcal polysaccharide vaccines; diphtheria tetanus ace… Read more